Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises STARK Group with its acquisition of FagFlis Group
Mandate

Vinge advises STARK Group with its acquisition of FagFlis Group

November 07, 2022 Banking and Finance EU, Competition and Regulatory Employment and Benefits Commercial Agreements M&A Real Estate and Construction

Vinge has advised STARK Group in connection with its acquisition of the Nordic tiles actor FagFlis Group with its Swedish operation FF Kakel AB. The group has conducted operations since 1981 and includes, in addition to the Swedish stores, approximately 30 facilities in Norway with total turnover of approximately NOK 750 million.

The transaction is estimated to be completed around the turn of the year 2022/2023, following approval by the Norwegian Competition Agency.

Vinge’s team consisted of, among others,  Jonas Bergström, Joacim Rydergård, Ellinor Wargenbrant and Tobias Onegård Karlsson (M&A), Frida Ställborn (Real Estate), Hedvig Ekdahl (Commercial Contracts), Ebba Svenburg (Employment Law), Karl-Gustaw Tobola (Banking and Finance), Sebastian Örndahl and Adam Löfquist (Competition Law) and Anna Ekdahl Roos (Project Assistant).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025